TLX
Telix Pharmaceuticals Ltd (TLX)
Healthcare • NASDAQ • $10.72+0.23%
- Symbol
- TLX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $10.72
- Daily Change
- +0.23%
- Market Cap
- $3.63B
- Trailing P/E
- 106.90
- Forward P/E
- -399.23
- 52W High
- $13.11
- 52W Low
- $6.28
- Analyst Target
- $20.67
- Dividend Yield
- 0.00%
- Beta
- 0.56
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The com…
Company websiteResearch TLX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.